Quantcast

Industry news that matters to you.  Learn more

Affymetrix and XRGenomics LTD to Collaborate on Development of a New Generation of Diagnostic Tests for Age-Related Diseases

Affymetrix, Inc. (NASDAQ: AFFX) and XRGenomics LTD, a UK based biotechnology company, announced today that they will collaborate on research and development of a new generation of diagnostic tests for age-related diseases. Over 50% of healthcare costs are spent on those aged 65 and older and according to the G8 Summit 2013, age-related diseases could bankrupt Western medicine by 2050. New solutions are required to deliver efficient and effective care.

Gentris Corporation Launches Next Generation Human Transcriptome Array

Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, recently announced that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip(R) Human Transcriptome Array (HTA) services. The GeneChip(R) HTA is a high resolution microarray for gene expression that is designed to empower next-generation expression profiling studies. The new array goes beyond gene-level expression profiling by providing the coverage and accuracy required to detect all known transcript isoforms produced by a gene.

Affymetrix Announces Research Collaboration With Centre for Proteomic and Genomic Research (CPGR) in South Africa

Affymetrix, Inc. (NASDAQ: AFFX) recently announced a research and service collaboration with the Centre for Proteomic and Genomic Research (CPGR) in South Africa. CPGR will provide gene expression and Axiom genotyping services to African researchers using GeneTitan® Multi-Channel (MC) Instrument. The Affymetrix and CPGR partnership aims to enable high-throughput genomics research and personalized medicine projects across Africa.

Affymetrix Launches Advanced RNA Amplification Technology for Whole-Genome Expression Analysis of FFPE Samples

Affymetrix, Inc. (NASDAQ:AFFX) announced today the availability of SensationPlus™ FFPE Amplification and 3’ IVT Labeling Kit (SensationPlus™ FFPE Reagent Kit), consisting of RNA amplification and labeling modules, to enable gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples on GeneChip® 3’ IVT arrays and Almac XcelTM Array for disease clinical research and retrospective studies.

Gentris Corporation Launches New Pharmacogenomics Services

Gentris Corporation, a global leader in pharmacogenomics and biorepository services, announced today that it has expanded its genomic biomarker services by incorporating multiple technology platforms into its 24,000 sq. ft., CLIA-certified, GLP-compliant laboratory. Gentris has integrated the Affymetrix GCS3000, Sequenom MassArray, and LifeTech Ion Torrent technologies in a continued effort to identify polymorphisms involved in drug response and adverse drug events as well as in determining somatic mutations in cancer.